FAQ

Ultralente Insulin

Known as: Insulin ultralente, Insulin, Ultralente [Chemical/Ingredient], Insulin, Ultralente 
A long-acting form of crystalline insulin often used in combination with a short-acting insulin in the treatment of diabetes mellitus. Administered… (More)

Topic mentions per year

Topic mentions per year

1978-2014
024619782014

Related topics

Related topics

10 relations

Broader (2)

Hypoglycemic AgentsInsulin
In BloodProcess of secretionadministration & dosageaspects of radiation effects
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Ultralente Insulin
physiological aspects
Hypoglycemic Agents
chemical synthesis
Insulin
standards characteristics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique
This single-dose, double-blind, randomised, parallel-group study evaluated the reproducibility in systemic exposure and… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2005
2005
Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
OBJECTIVE Multiple daily insulin injection programs are commonly accompanied by considerable glycemic variation and hypoglycemia… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study.
BACKGROUND Effective glycaemic control in type 1 diabetes mellitus usually requires two or more insulin injections daily. Inhaled… (More)
Is this relevant?
2001
2001
Inhaled human insulin treatment in patients with type 2 diabetes mellitus.
BACKGROUND Despite demonstrated benefits, intensive insulin therapy has not gained widespread clinical acceptance for several… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
OBJECTIVE Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin) is a biosynthetic insulin analog with a prolonged… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
1999
1999
Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen.
OBJECTIVE In this study, we evaluated the effects of high-(55%) and low-(40%) carbohydrate diets on insulin requirements in nine… (More)
Is this relevant?
1988
1988
Strict insulin therapy normalises organ nitrogen contents and the capacity of urea nitrogen synthesis in experimental diabetes in rats
Rats with experimental diabetes due to streptozotocin (75 mg/kg body weight) and free access to food were divided into two groups… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
1986
Highly Cited
1986
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
Two groups of adult male Munich-Wistar rats and a third group of nondiabetic age-matched and weight-matched normal control rats… (More)
  • table I
  • figure 1
  • table II
  • figure 2
  • table III
Is this relevant?
Highly Cited
1985
Highly Cited
1985
Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy.
Six groups of Munich-Wistar rats underwent micropuncture study 2-10 weeks and morphologic studies 11-13 months after induction of… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
1985
1985
The subcutaneous absorption of human and bovine ultralente insulin formulations.
The subcutaneous absorption of 125I-labelled semisynthetic human ultralente insulin was compared with that of 125I-labelled beef… (More)
Is this relevant?